|
2 Companies |
|
0 Products |
|
0 Products |
|
2 Mechanisms of Action |
|
0 Trials |
|
5 News |
|
- | NN1213 / Novo Nordisk
Trial completion, Gene therapy: Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID) (clinicaltrials.gov) - Jun 30, 2017
P1, N=3, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=40, Completed, Sponsor: National Human Genome Research Institute (NHGRI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Increlex (mecasermin) / Ipsen
Trial termination: Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1 (clinicaltrials.gov) - Jul 6, 2015
P1/2, N=6, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Completed --> Terminated; Insufficient patient participation
- Increlex (mecasermin) / Ipsen
Trial completion: Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1 (clinicaltrials.gov) - Dec 6, 2012
P1/2, N=6, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Completed --> Terminated; Insufficient patient participation Active, not recruiting --> Completed
- Increlex (mecasermin) / Ipsen
Enrollment change: Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1 (clinicaltrials.gov) - Jan 18, 2012
P1/2, N=6, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed N=10 --> 6